Role of breast cancer resistance protein (Bcrp1/Abcg2) in the extrusion of glucuronide and sulfate conjugates from enterocytes to intestinal lumen

被引:70
作者
Adachi, Y
Suzuki, H
Schinkel, AH
Sugiyama, Y [1 ]
机构
[1] Univ Tokyo, Sch Pharmaceut Sci, Tokyo, Japan
[2] Netherlands Canc Inst, Div Expt Therapy, Amsterdam, Netherlands
关键词
D O I
10.1124/mol.104.007393
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The purpose of this study is to examine the significance of efflux transporters in the small intestine to extrude glucuronide (G) and sulfate (S) conjugates into the intestinal lumen. From this standpoint, we performed in situ intestinal perfusion experiments by using Eisai hyperbilirubinemic rats ( EHBRs) in which the multidrug resistance protein 2 (Mrp2/Abcc2) is hereditarily defective and breast cancer resistance protein (Bcrp1/Abcg2) knockout mice. The intestinal lumen of EHBRs and Bcrp1 (-/-) mice was perfused with medium containing 4-methylumbelliferone ( 4MU) and E3040 [6-hydroxy-5,7-dimethyl-2-methylamino4-(3-pyridilmethyl) benzothiazole] to determine the efflux of metabolites into the outflow. The efflux of E3040-glucuronide ( G) in EHBRs was significantly lower compared with that in normal rats. However, no significant difference was observed for the efflux of 4MU-G, 4MU-sulfate (S), and E3040-S between EHBRs and normal rats. In contrast, the efflux of intracellularly formed 4MU-G, 4MU-S, and E3040-G in Bcrp1 (-/-) mice was significantly lower than that in normal mice. Therefore, Bcrp1 has an important role in extruding glucuronide and sulfate conjugates formed in enterocytes into the intestinal lumen, whereas Mrp2 is responsible for the efflux of some glucuronide conjugates.
引用
收藏
页码:923 / 928
页数:6
相关论文
共 28 条
  • [1] Quantitative evaluation of the function of small intestinal P-glycoprotein:: Comparative studies between in situ and in vitro
    Adachi, Y
    Suzuki, H
    Sugiyama, Y
    [J]. PHARMACEUTICAL RESEARCH, 2003, 20 (08) : 1163 - 1169
  • [2] Gastrointestinal absorption of drugs: methods and studies
    Barthe, L
    Woodley, J
    Houin, G
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1999, 13 (02) : 154 - 168
  • [3] Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery
    Benet, LZ
    Izumi, T
    Zhang, YC
    Silverman, JA
    Wacher, VJ
    [J]. JOURNAL OF CONTROLLED RELEASE, 1999, 62 (1-2) : 25 - 31
  • [4] Chen WZ, 1997, J IRON STEEL RES INT, V4, P31
  • [5] The mucosa of the small intestine - How clinically relevant as an organ of drug metabolism?
    Doherty, MM
    Charman, WN
    [J]. CLINICAL PHARMACOKINETICS, 2002, 41 (04) : 235 - 253
  • [6] Gotoh Y, 2000, J PHARMACOL EXP THER, V292, P433
  • [7] Honjo Y, 2001, CANCER RES, V61, P6635
  • [8] Catalog of 605 single-nucleotide polymorphisms (SNPs) among 13 genes encoding human ATP-binding cassette transporters:: ABCA4, ABCA7, ABCA8, ABCD1, ABCD3, ABCD4, ABCE4, ABCF1, ABCG1, ABCG2, ABCG4, ABCG5, and ABCG8
    Iida, A
    Saito, S
    Sekine, A
    Mishina, C
    Kitamura, Y
    Kondo, K
    Harigae, S
    Osawa, S
    Nakamura, Y
    [J]. JOURNAL OF HUMAN GENETICS, 2002, 47 (06) : 285 - 310
  • [9] The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria
    Jonker, JW
    Buitelaar, M
    Wagenaar, E
    van der Valk, MA
    Scheffer, GL
    Scheper, RJ
    Plösch, T
    Kuipers, F
    Elferink, RPJO
    Rosing, H
    Beijnen, JH
    Schinkel, AH
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (24) : 15649 - 15654
  • [10] Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan
    Jonker, JW
    Smit, JW
    Brinkhuis, RF
    Maliepaard, M
    Beijnen, JH
    Schellens, JHM
    Schinkel, AH
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (20): : 1651 - 1656